New Insights into Muscle Aging: Cardiolipin's Role Revealed
Research from the University of Copenhagen uncovers how a molecule called cardiolipin affects muscle strength in aging.
Aging muscles shift towards slow-twitch fibers, sacrificing strength for cellular protection.
Cardiolipin levels decline in aging muscles, impacting mitochondrial function.
Restoring cardiolipin in mice reversed muscle wasting and prevented premature death.
A groundbreaking study conducted by scientists at the University of Copenhagen has unveiled a hidden mechanism behind muscle weakening associated with aging. The research, published on October 28, 2026, highlights how a molecule known as cardiolipin plays a crucial role in muscle fiber transformation, leading to a shift towards slower-twitch fibers that prioritize cellular protection over strength.
Historically, muscle deterioration has been a significant concern as individuals age, with a notable decline in strength and efficiency of mitochondria, the energy-producing structures within cells. This study reveals that aging muscles increasingly rely on slow-twitch fibers, which are less efficient but help protect muscle cells from damage. The researchers sought to understand why muscles would depend on a less effective energy system, leading them to focus on cardiolipin, a specialized fat molecule essential for mitochondrial function.
The investigation revealed that cardiolipin levels decrease in both human and mouse muscle mitochondria as they age, resulting in structural abnormalities and loss of function. Experimental reduction of cardiolipin in young mice mimicked the aging process, causing a shift from fast-twitch to slow-twitch fibers. Remarkably, restoring cardiolipin levels reversed muscle wasting and prevented premature deaths in affected mice, indicating its potential as a therapeutic target.
The implications of this research extend beyond individual health, as it opens avenues for new treatments for age-related muscle decline. The findings suggest that therapies aimed at restoring cardiolipin levels or modulating the protective adaptations regulated by ERRγ, a protein involved in muscle fiber transition, could be effective. Current FDA-approved medications targeting cardiolipin and ongoing research into ERRγ present promising opportunities for addressing muscle aging.
Looking ahead, researchers are optimistic about the potential for clinical applications. The next steps involve exploring methods to enhance cardiolipin levels in aging muscles and further investigating ERRγ's role in muscle adaptation. As the study indicates, even partial recovery of cardiolipin can lead to significant improvements in muscle health, paving the way for innovative treatments in the future.
